Study: Cannabidiol Holds Promise For Treating Psychosis

Cananbidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.

Investigators in the Netherlands and in the United Kingdom reviewed preclinical and clinical data on the use of CBD as an antipsychotic agent. Authors reported that both animal and human studies document the ability of CBD to mitigate symptoms of psychosis. Specifically, CBD administration is associated with improved symptoms in clinical evaluations of patients with schizophrenia, Parkinson’s disease, and ketamine-induced dissociative and psychotic symptoms.

Investigators also highlighted a 2012 double-blind, randomized placebo-controlled trial assessing CBD versus the prescription anti-psychotic drug amisulpride in 42 subjects with schizophrenia and acute paranoia. Authors reported that both CBD and the prescription drug were associated with “equally significant clinical improvement” in this patient population, but that cannabidiol “possessed significantly less side effects.”

Researchers concluded: “[E]vidence from several study domains suggests that CBD has some potential as an antipsychotic treatment. … Given the high tolerability and superior cost-effectiveness, CBD may prove to be an attractive alternative to current antipsychotic treatment.”

Previous human trials assessing the administration of CBD in healthy human subjects report that the cannabinoid is “safe and well tolerated.”

Separate investigations of CBD, primarily in animal models, have documented the cannabinoid to possess a variety of therapeutic qualities, including anti-inflammatory, anti-diabetic, anti-epileptic, anti-cancer, and bone-stimulating properties. Recently, the FDA approved the experimental use of CBD extracts for the treatment of a rare form of intractable pediatric epilepsy known as Dravet syndrome. Preliminary clinical trials assessing the safety and tolerability of the compound in children are scheduled to begin imminently.

Full text of the study, entitled “Cannabidiol as a potential treatment for psychosis,” appears online here.

106 thoughts

  1. I read story on a website about this girl who starts using 100mg cbd daily after 8 years of being hospitalized in n out after trying to leave antipsychotic but with the use of cbd she was able to come off of antipsychotic for atleast a year that I know off she was on 50mg of cbd from naturalwonoil.com or endoca.com was her source of cbd

  2. Hira, I believe there’s enough evidence at this point that shows Cannabidiol treats psychosis effectively. Unlike atypical anti-psychotics CBD is natural which means less unwanted side effects. The greatest benefit of being natural is once you grow a tolerance to CBD doctors will feel more comfortable increasing dosage.

    Anyhow there is currently a bill which would allow CBD from cannabis to be removed as a controlled substances. please visit this site and shoot an email to your representatives.

    http://www.coalitionforaccessnow.org/take_action

  3. Looks like it really does help treat Schizophrenia as there are positive results from GW Pharmaceuticals Phase 2 clinical trials released today. Awesome!

    Over a series of exploratory endpoints, CBD was consistently superior to placebo, with the most notable differences being in the PANSS positive sub-scale (p=0.018), the Clinical Global Impression of Severity (p=0.04) and Clinical Global Impression of Improvement (p=0.02). The proportion of responders (improvement in PANSS Total score greater than 20%) on CBD was higher than that of participants on placebo, with an Odds Ratio of 2.65. In the area of cognition, CBD was superior to placebo (p=0.07) with marked differences being seen in sub-domains of particular relevance to improving the outlook for people suffering with schizophrenia. With respect to negative symptoms, the Scale for Assessment of Negative Symptoms showed a trend in favour of CBD which reached statistical significance for patients taking CBD together with one of the leading first line anti-psychotic medications. The majority of other endpoints in the study were in favor of CBD and approached statistical significance in many cases.

    http://finance.yahoo.com/news/gw-pharmaceuticals-announces-positive-proof-130000370.html

    Now if only Quinn was still governor of Il…

  4. Hey, I think your website might be having browser compatibility issues.
    When I look at your blog site in Firefox, it looks fine but
    when opening in Internet Explorer, it has some overlapping.
    I just wanted to give you a quick heads up! Other then that, awesome blog!

Leave a Reply